3 deals
Investor · 2 deals
SymBiosis
Disclosed deals
Every published round SymBiosis took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio | |
| AdvanCell | Series C | 12 Feb 2025 | $178m | Lead | Forbes Australia, SmartCompany, Startup Daily, Brandon Capital |
Portfolio
Companies SymBiosis has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | Produces radiopharmaceuticals that target cancer cells without the typical collateral dam… | 12 Feb 2025, Series C | 2 | 1 |
Funds
Fund closes reported for SymBiosis, as distinct from the investments it has made.
Portfolio companies acquired
Companies SymBiosis has backed that another company then bought. An exit for the holding, not a deal SymBiosis did.
People
Coverage
Stories naming SymBiosis. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Series C
US$112m
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.